Supplementary material: A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article</b><b> </b><b>'</b><b>A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study</b><b>'</b><b> </b><b>published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research.</i></b></p><ul><li><b>Supplemental figure 1: </b>Pictorial representation of the trial emulation study comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy using calibration and indirect treatment comparison methods</li><li><b>Supplemental table 1:</b> Exclusion criteria to align the real-world tafamidis cohort with ATTR-ACT</li><li><b>Supplemental table 2: </b>Exclusion criteria to align the real-world tafamidis cohort with ATTRibute-CM</li><li><b>Supplemental table 3:</b> Attrition for the real-world tafamidis cohort using ATTR-ACT criteria</li><li><b>Supplemental table 4:</b> Attrition for the real-world tafamidis cohort using ATTRibute-CM criteria</li><li><b>Supplemental table 5: </b>Distributions used for the Monte Carlo simulation</li><li><b>Supplemental table 6:</b> Pre- and post-ATTR-ACT trial-emulated real-world cohort characteristics compared to ATTR-ACT trial aggregate data</li><li><b>Supplemental table 7:</b> Pre- and post-ATTRibute-CM trial-emulated real-world cohort characteristics compared to ATTRibute-CM trial aggregate data</li><li><b>Supplemental table 8:</b> Baseline characteristics of patients included in the (pre-MAIC) ATTRibute-CM-like tafamidis cohort compared to patients excluded from the cohort due to missing NT-proBNP data</li><li><b>References</b></li></ul><p dir="ltr"><b>Aim:</b> Tafamidis and acoramidis are transthyretin stabilizers approved for the treatment of transthyretin amyloid cardiomyopathy.

We compared the effectiveness of acoramidis versus tafamidis regarding allcause mortality (ACM). <b>Materials & methods:</b> This study used a hybrid design to compare 42-month ACM with acoramidis versus tafamidis using trial emulation, calibration, and indirect treatment comparison. Two real-world cohorts of participants initiating tafamidis were identified from TriNetX (2019–2024) using observational analogues to emulate ATTR-ACT and ATTRibute-CM trial eligibility criteria and baseline characteristics.